Greek court awards ‘exceptional’ €100,000 as moral prejudice damages for patent infringement

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Greek court awards ‘exceptional’ €100,000 as moral prejudice damages for patent infringement

Sponsored by

patrinos-logo.png
Statue of the Lady of Justice against a backdrop of the Greek flag

Constantinos Kilimiris of Patrinos & Kilimiris says the unusually high award signals a potential shift in how Greek courts assess non‑pecuniary harm in infringement cases

Under Greek patent law, a patentee may seek, among other remedies, compensation for the moral harm suffered as a result of infringement. In practice, however, Greek courts tend to award relatively modest sums for such damages and rarely uphold claims exceeding €40,000.

Against this background, a recent judgment of the Athens Full Member First Instance Court, delivered in the context of a main action for patent infringement concerning a blockbuster pharmaceutical product, stands out as exceptional. In that case, the court awarded the patentee €100,000 in moral damages, significantly departing from the typically conservative approach.

In the case at issue, the patentee – an innovator pharmaceutical company – brought an infringement action against a generic manufacturer that had launched its product ‘at risk’. In addition to its infringement claims, the patentee sought compensation for moral damages.

The defendant contested this claim, arguing that the claimant had failed to identify any concrete harm and that the legal requirements for establishing moral damages had not been met.

The court dismissed this objection. It held that the generic product had been marketed at significantly lower prices than the patented reference product, which directly affected patients receiving treatment with the reference product by incentivising them to switch to the cheaper alternative. The court found that this development had a serious adverse impact on the claimant’s name and reputation, both among healthcare professionals and patients. In particular, it led to a sudden and unexpected increase in patient co-payments at a time when the claimant’s patent remained valid and in force.

The court further concluded that these circumstances resulted in a diminution of the patent’s economic value, as well as a decline in the claimant’s prestige, reputation, and public confidence in its products. Moreover, the defendant’s conduct created the impression among business partners, healthcare professionals, and the public that the invention lacked uniqueness or commercial success, and that the patentee was unable to adequately protect its rights despite holding a valid patent.

In light of the foregoing, the court held that the claimant had suffered moral harm and was entitled to reasonable monetary compensation, irrespective of any additional pecuniary loss. Taking into account all relevant factors, including the claimant’s long-standing and costly efforts to develop the patented product, the court assessed moral damages at €100,000.

This decision is likely to serve as a benchmark in future cases involving similar infringement scenarios, particularly with respect to the assessment and quantification of moral damages in pharmaceutical litigation.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article